RT Journal Article
T1 Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis.
A1 Cerezuela-Fuentes, Pablo
A1 Gonzalez-Cao, Maria
A1 Puertolas, Teresa
A1 Manzano, Jose Luis
A1 Maldonado, Cayetana
A1 Yelamos, Oriol
A1 Berciano-Guerrero, Miguel A
A1 Martin-Liberal, Juan
A1 Muñoz-Couselo, Eva
A1 Espinosa, Enrique
A1 Drozdowskyj, Ana
A1 Berrocal, Alfonso
A1 Soria, Ainara
A1 Marquez-Rodas, Ivan
A1 Martin-Algarra, Salvador
A1 Quindos, Maria
A1 Puig, Susana
K1 Access
K1 Innovative therapies
K1 Non-melanoma skin cancer
AB Background Novel and highly efective drugs for non-melanoma skin cancer (NMSC) improve patient outcomes, but their high cost strains healthcare systems. Spain’s decentralized public health system, managed by 17 autonomous communities (AaCc), raises concerns about equitable access. Methods A cross-sectional survey (July–September 2023) was sent to Spanish Multidisciplinary Melanoma Group (GEM Group) members to assess access to new drugs. Findings Fifty physicians from 15 Spanish AaCc responded to the survey. Access for drug with approved public reimbursement, Hedgehog inhibitors in basal-cell carcinoma and anti PD-L1 antibody in Merkel carcinoma, was observed in 84% and 86% of centers, respectively. For other EMA-approved treatments, but without reimbursement in Spain access decreased to 78% of centers. Heterogeneity in access was mainly observed intra regions. Conclusion Unequal fnancial support for drugs for NMSC with creates a patchwork of access across Spanish hospitals, with variations even within the same AaCc.
PB Springer
SN 1699-048X
YR 2024
FD 2024-07-01
LK https://hdl.handle.net/10668/28505
UL https://hdl.handle.net/10668/28505
LA en
NO Cerezuela-Fuentes P, Gonzalez-Cao M, Puertolas T, Manzano JL, Maldonado C, Yelamos O, et al. Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis. Clin Transl Oncol. 2025 Jan;27(1):386-391
DS RISalud
RD Aug 24, 2025